



George Puenea

Date of birth: 06/07/1978 | **Nationality:** Romanian | **Gender:** Male | **Phone number:**

(+40) 0722438747 (Mobile) | **Email address:** george.puenea@gmail.com |

Address: Oxigen nr.10, 307160, Dumbravita, Romania (Home)

WORK EXPERIENCE

LECTURER - UNIVERSITY OF MEDICINE AND PHARMACY " VICTOR BABEȘ " - 01/09/2024 - Current - TIMISOARA, ROMANIA

ASSISTANT PROFESSOR - UNIVERSITY OF MEDICINE AND PHARMACY " VICTOR BABEȘ " - 26/02/2007 - 31/08/2024

RESIDENT GENERAL SURGERY - COUNTY HOSPITAL - 01/02/2020 - Current

CO FOUNDER MEDICAL.33 - 01/09/2022 - Current - TIMIȘOARA, ROMANIA

MANAGER - NOVALIFE CLINICS - 20/10/2017 - Current

MANAGER - CARDINAL MED - 01/02/2012 - 31/10/2016

PRIMARY CARE PHYSICIAN MEDICAL REHABILITATION - UNIVERSITY OF MEDICINE AND PHARMACY " VICTOR BABEȘ " - 03/09/2021 - Current

MEDICAL SALES REPRESENTATIVE - SANDOZ PHARMA - 20/01/2017 - 19/10/2017

SPECIALIST DOCTOR MEDICAL REHABILITATION - UNIVERSITY OF MEDICINE AND PHARMACY " VICTOR BABEȘ " - 13/06/2012 - 02/09/2021

RESIDENT DOCTOR REHABILITATION MEDICINE - UNIVERSITY OF MEDICINE AND PHARMACY " VICTOR BABEȘ " - 01/01/2007 - 13/06/2012

MEDICAL SALES REPRESENTATIVE - A&D PHARMA - 17/07/2006 - 15/09/2010

MEDICAL INTERN - "LOUIS ȚURCANU" HOSPITAL - 01/01/2005 - 31/12/2005

EDUCATION AND TRAINING

21/01/2014 - CURRENT Timișoara, Romania

DOCTOR IN THE FIELD OF MEDICINE Universitatea de Medicină și Farmacie " Victor Babeș "

Address Piața Eftimie Murgu nr. 2, 300041, Timișoara, Romania

01/01/2006 - 31/12/2009 Vienna, Austria

EUROPEAN BUSINESS COMPETENCE LICENCE International Centre of IBC*L

Address Piața Eftimie Murgu nr. 2, 300041, Timișoara, Romania**LANGUAGE SKILLS**Mother tongue(s): **ROMANIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	B2	B2	B2	B2	B2

*Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user***SKILLS**

Microsoft Office (Word, Excel, Power Point) | Google (Google Meet, Google Docs, Google Classroom, Google Drive, Google Site) | Advanced Computer Skills | Advanced Computer Knowledge

CLINICAL TRIALS**Coordinator, co investigator and principal investigator**

1.A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One of the Preceding Phase IIb Studies with ALX-0061.2015.

(Co investigator)

2.A Phase IIb Multicenter, Randomized, Double-blind, PlaceboControlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy.2015.

(Co investigator)

3.A Phase IIb Multicenter, Randomized, Double-blind, Study of ALX-0061 Administered Subcutaneously as Monotherapy in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methotrexate or for whom Continued Methotrexate Treatment is Inappropriate.2015.

(Co investigator)

4.A phase II,multicenter,randomized,parallel groups study to assess the efficacy and safety of two dose levels(0,5 mg and 1 mg)Tizaspray administered intranasally versus Sirdalud 4 mg,in patients witch acute low back pain.2014.

(Co investigator and study coordinator)

5.Phase 2, Multi-dose, Double-blind, Placebo – controled, Randomized, Multicenter study of MDX- 1100 (anti-CXCL 10 Human Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis, Sub- investigator,2008-2009.

Coordonator, investigator principal, co investigator studii clinice

6.A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms in Subjects with Rheumatoid Arthritis, Sub-investigator, 2008-2009.

7.A study to determine the safety, efficacy and pharmacokinetics of 80mg, 160mg, and 320mg ALD518 versus placebo administered as multiple intravenous infusions to patients with active rheumatoid arthritis who have had an inadequate response to methotrexate., Sub-investigator, 2008- 2009.

8.Open,comparative study to evaluate the performance and safety of the medical device Ainara vaginal gel versus a hyaluronic acid-based gel in menopausal transition women affected by vaginal dryness.2019-2020.

(Study coordinator)

9.Open non-comparative study to evaluate the performance and safety of the medical device AINARA vaginal gel, in post-menopausal women affected by vaginal dryness.2019-2020.

(Study coordinator)

10.Post marketing clinical follow up study to evaluate performance, safety, and quality of life in late menopausal transition and post-menopausal women treated with the medical device AINARA vaginal gel for vaginal dryness for 6 monyhs.2019-2020.

(Study coordinator)

11.Pilot open non-comparative study to evaluate in special care setting the administration of the new nutraceutical associated with sleep hygiene guidlines in subjects affected by persistent mild sleep disorders(difficulty in initiating sleep for at least 1 month and reduced quality of sleeping).2019-2020.

(Study coordinator)

12. Randomized, double blind, placebo-controlled clinical trial to assess the efficacy of ySMIN PLUS (dietary supplement) in chronic venous insufficiency symptoms relief. 2019-2020.

(Sub investigator and study coordinator)

13. Pilot, open non-controlled trial to assess the feasibility of implementing objective parameters as primary endpoints in a clinical trial with patients affected by knee osteoarthritis. 2018-2020

(Principal investigator and study coordinator)

● **MANAGEMENT AND LEADERSHIP SKILLS**

Organisational / managerial skills

MANAGEMENT AND LEADERSHIP SKILLS

COMMUNICATION SKILLS

COLLABORATION SKILLS

CRITICAL THINKING SKILLS

FINANCE SKILLS

PROJECT MANAGEMENT SKILLS